

Elihu Estey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2868019/publications.pdf>

Version: 2024-02-01

168
papers

20,212
citations

41344

49
h-index

10734

138
g-index

176
all docs

176
docs citations

176
times ranked

14239
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. <i>Blood</i> , 2022, 139, 323-332.	1.4	80
2	The wider perspective: twenty years of clinical trials inÂmyelodysplastic syndromes. <i>British Journal of Haematology</i> , 2022, 196, 329-335.	2.5	9
3	More general incorporation of hemoglobin level into response criteria for myelodysplastic syndrome and acute myeloid leukemia with increase in minimum red cell transfusion levels. <i>Leukemia and Lymphoma</i> , 2022, 63, 514-517.	1.3	0
4	Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignancies. <i>Leukemia</i> , 2022, , .	7.2	0
5	Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm. <i>Leukemia</i> , 2022, , .	7.2	0
6	Intensive chemotherapy for acute myeloid leukemia relapse after allogeneic hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	3
7	Lamin B1 deletion in myeloid neoplasms causes nuclear anomaly and altered hematopoietic stem cell function. <i>Cell Stem Cell</i> , 2022, 29, 577-592.e8.	11.1	13
8	Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing. <i>Leukemia Research</i> , 2022, 115, 106822.	0.8	2
9	Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 1411-1417.	4.1	8
10	Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. <i>Haematologica</i> , 2021, 106, 2114-2120.	3.5	4
11	New treatments for acute myeloid leukemia: how much has changed?. <i>Leukemia</i> , 2021, 35, 45-46.	7.2	7
12	Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2021, 62, 234-238.	1.3	4
13	Are phase III trials still important for FDA drug approval?. <i>Leukemia and Lymphoma</i> , 2021, 62, 1287-1288.	1.3	1
14	Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML). <i>Leukemia and Lymphoma</i> , 2021, 62, 1532-1535.	1.3	3
15	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
16	Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1226-1233.	1.3	24
17	Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 27-36.	4.9	4
18	Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy. <i>Leukemia and Lymphoma</i> , 2021, , 1-10.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Loss of Lamin B1 in Myeloid Neoplasms with 5q Deletion Causes Myeloid-Biased Hematopoiesis and Pelger-Huet Nuclear Anomaly. <i>Blood</i> , 2021, 138, 502-502.	1.4	0
20	Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of "Positive" Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 - 2015. <i>Blood</i> , 2021, 138, 4040-4040.	1.4	0
21	Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. <i>Leukemia</i> , 2020, 34, 635-639.	7.2	11
22	Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?. <i>Leukemia</i> , 2020, 34, 671-681.	7.2	46
23	Need for routine examination of left ventricular ejection fraction in patients with AML. <i>Leukemia</i> , 2020, 34, 1169-1171.	7.2	1
24	Truth or consequences: under-reporting of post-accrual changes in clinical trial design. <i>Leukemia and Lymphoma</i> , 2020, 61, 2034-2035.	1.3	0
25	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 3239-3245.	5.2	19
26	Acute myeloid leukemia: 2021 update on risk-stratification and management. <i>American Journal of Hematology</i> , 2020, 95, 1368-1398.	4.1	74
27	Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. <i>Leukemia Research</i> , 2020, 89, 106298.	0.8	14
28	Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. <i>Blood Reviews</i> , 2020, 44, 100679.	5.7	26
29	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood Advances</i> , 2020, 4, 611-616.	5.2	21
30	Incidence and Prognostic Impact of Crh in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
31	Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 12-13.	1.4	0
32	Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 12-13.	1.4	1
33	Chromosomal Abnormalities and Prognosis in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 2632-2642.	1.6	77
34	Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3121-3130.	4.1	11
35	Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e633-e635.	0.4	0
36	New study-designs to address the clinical complexity of acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 567-569.	7.2	7

#	ARTICLE	IF	CITATIONS
37	More Versus Less Therapy for Older Adults With Acute Myeloid Leukemia: New Perspectives on an Old Debate. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 421-432.	3.8	31
38	Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification. JAMA Oncology, 2019, 5, 1062.	7.1	14
39	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 2019, 133, 1630-1643.	1.4	393
40	“Looking beyond survival to define therapeutic value in acute myeloid leukemia”™. Leukemia and Lymphoma, 2019, 60, 1107-1109.	1.3	1
41	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. Leukemia, 2019, 33, 554-558.	7.2	8
42	Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia, 2019, 33, 371-378.	7.2	9
43	A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leukemia and Lymphoma, 2019, 60, 1023-1029.	1.3	7
44	Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT). Blood, 2019, 134, 4585-4585.	1.4	1
45	Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms. Blood, 2019, 134, 1364-1364.	1.4	4
46	Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow. Blood, 2019, 134, 2729-2729.	1.4	1
47	Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms. Blood, 2019, 134, 3824-3824.	1.4	2
48	Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML). Blood, 2019, 134, 260-260.	1.4	3
49	Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid leukemia (AML)?. Journal of Clinical Oncology, 2019, 37, 7031-7031.	1.6	4
50	Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia. Blood, 2019, 134, 4674-4674.	1.4	0
51	Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data. Blood, 2019, 134, 291-291.	1.4	3
52	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. Biology of Blood and Marrow Transplantation, 2018, 24, 1615-1620.	2.0	29
53	Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica, 2018, 103, e106-e109.	3.5	19
54	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia, 2018, 32, 2352-2362.	7.2	39

#	ARTICLE	IF	CITATIONS
55	Time to repeal and replace response criteria for acute myeloid leukemia?. Blood Reviews, 2018, 32, 416-425.	5.7	51
56	Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development. Current Medical Research and Opinion, 2018, 34, 2031-2039.	1.9	22
57	Allogeneic Transplantation for Acute Myelogenous Leukemia in CR1. Biology of Blood and Marrow Transplantation, 2018, 24, 205-206.	2.0	2
58	Acute myeloid leukemia: 2019 update on riskâ€stratification and management. American Journal of Hematology, 2018, 93, 1267-1291.	4.1	283
59	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2018, 19, 889-903.	10.7	205
60	Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). Journal of Drug Assessment, 2018, 7, 51-53.	2.2	25
61	New drugs in AML: uses and abuses. Leukemia, 2018, 32, 1479-1481.	7.2	12
62	E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML. Blood, 2018, 132, 1513-1513.	1.4	3
63	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. Blood, 2018, 132, 3978-3978.	1.4	0
64	Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia. Blood Reviews, 2017, 31, 185-192.	5.7	83
65	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129, 424-447.	1.4	4,375
66	Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 2017, 129, 1275-1283.	1.4	214
67	Development and Validation of a Novel Acute Myeloid Leukemiaâ€Composite Model to Estimate Risks of Mortality. JAMA Oncology, 2017, 3, 1675.	7.1	125
68	Emerging treatments in acute myeloid leukemia: current standards and unmet challenges. Clinical Advances in Hematology and Oncology, 2017, 15, 632-642.	0.3	6
69	Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?. Leukemia and Lymphoma, 2016, 57, 1205-1207.	1.3	1
70	Why are there so few randomized trials for patients with primary refractory acute myeloid leukemia?. Best Practice and Research in Clinical Haematology, 2016, 29, 324-328.	1.7	9
71	Acute Myeloid Leukemia â€” Many Diseases, Many Treatments. New England Journal of Medicine, 2016, 375, 2094-2095.	27.0	20
72	Acute myeloid leukemia: 2016 Update on riskâ€stratification and management. American Journal of Hematology, 2016, 91, 824-846.	4.1	49

#	ARTICLE	IF	CITATIONS
73	Acute myeloid leukaemia. Nature Reviews Disease Primers, 2016, 2, 16010.	30.5	277
74	Variability in management of hematologic malignancy patients with venous thromboembolism and chemotherapy-induced thrombocytopenia. Thrombosis Research, 2016, 141, 104-105.	1.7	15
75	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Diseaseâ€‘Based Definition of Complete Remission?. Journal of Clinical Oncology, 2016, 34, 329-336.	1.6	347
76	Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival. Blood, 2016, 128, 1613-1613.	1.4	6
77	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. Blood, 2016, 128, 216-216.	1.4	18
78	Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML). Blood, 2016, 128, 4050-4050.	1.4	43
79	Rates of CR with and without Measurable Residual Disease after Induction Treatment with "7+3" or Azacitidine/Decitabine for Newly-Diagnosed AML. Blood, 2016, 128, 2792-2792.	1.4	0
80	Current challenges in clinical development of â€‘targeted therapiesâ€‘: the case of acute myeloid leukemia. Blood, 2015, 125, 2461-2466.	1.4	71
81	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. Haematologica, 2015, 100, e409-e411.	3.5	10
82	Reply to D. Przepiorka et al. Journal of Clinical Oncology, 2015, 33, 3676-3677.	1.6	12
83	Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica, 2015, 100, 927-934.	3.5	93
84	Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 546-551.	2.0	30
85	Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. Haematologica, 2015, 100, e97-e98.	3.5	16
86	Why Is Progress in Acute Myeloid Leukemia So Slow?. Seminars in Hematology, 2015, 52, 243-248.	3.4	20
87	Prognostic Significance of <i>NPM1</i> Mutations in the Absence of <i>FLT3</i> â€‘Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report. Journal of Clinical Oncology, 2015, 33, 1157-1164.	1.6	113
88	Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 1258-1264.	1.6	223
89	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. Haematologica, 2015, 100, e254-e256.	3.5	3
90	Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome. JAMA Oncology, 2015, 1, 1120.	7.1	43

#	ARTICLE	IF	CITATIONS
91	Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 782-784.	1.3	3
92	Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2569-2569.	1.4	1
93	A multicenter, open-label phase 2a study of ibrutinib with or without cytarabine in patients with acute myeloid leukemia (PCYC-1131).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS7096-TPS7096.	1.6	1
94	Oncology Providers Ability to Prognosticate Patient Outcomes: An Analysis of the Survey on Provider Assessment of Risk (SPAR) Study. <i>Blood</i> , 2015, 126, 5635-5635.	1.4	0
95	Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin. <i>Blood</i> , 2015, 126, 3776-3776.	1.4	0
96	Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2015, 126, 1339-1339.	1.4	0
97	An Automated System for Parsing and Risk Classifying Karyotype Nomenclature for Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2602-2602.	1.4	1
98	Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials. <i>Blood</i> , 2015, 126, 688-688.	1.4	0
99	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 21-33.	2.5	31
100	Acute myeloid leukemia: 2014 Update on riskâ€stratification and management. <i>American Journal of Hematology</i> , 2014, 89, 1063-1081.	4.1	131
101	Primacy of Resistance Rather Than Toxicity in Determining Outcome of Therapy for AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S56-S58.	0.4	5
102	Management of persistent AML at day 14. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 235-240.	1.7	6
103	The past and future of CD33 as therapeutic target in acute myeloid leukemia. <i>Blood Reviews</i> , 2014, 28, 143-153.	5.7	145
104	Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 549-555.	2.0	47
105	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 3249-3256.	1.6	361
106	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, 986-996.	10.7	549
107	A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 395-400.e1.	0.4	11
108	Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model. <i>Leukemia Research</i> , 2014, 38, 258-262.	0.8	5

#	ARTICLE	IF	CITATIONS
109	Evaluation of early discharge after hospital treatment of neutropenic fever in acute myeloid leukemia (AML). <i>Leukemia Research Reports</i> , 2013, 2, 26-28.	0.4	2
110	Frequency of Allogeneic Hematopoietic Cell Transplantation Among Patients With High- or Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission. <i>Journal of Clinical Oncology</i> , 2013, 31, 3883-3888.	1.6	42
111	Are immunoconjugates approaching "standard of care" in AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 261-268.	1.7	0
112	Acute myeloid leukemia: 2013 update on risk stratification and management. <i>American Journal of Hematology</i> , 2013, 88, 317-327.	4.1	234
113	The NCI common toxicity criteria and treatment-associated mortality in acute myeloid leukemia. <i>Blood</i> , 2013, 122, 293-294.	1.4	5
114	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. <i>Blood</i> , 2013, 122, 1813-1821.	1.4	325
115	Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 1311.	3.0	55
116	The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. <i>Blood</i> , 2013, 122, 356-356.	1.4	11
117	Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic. <i>Blood</i> , 2013, 122, 3924-3924.	1.4	6
118	Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG. <i>Blood</i> , 2013, 122, 3925-3925.	1.4	5
119	Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study. <i>Blood</i> , 2013, 122, 3936-3936.	1.4	2
120	Personalized Approach To Treatment of Acute Myeloid Leukemia Using a High-Throughput Chemosensitivity Assay. <i>Blood</i> , 2013, 122, 483-483.	1.4	2
121	Assessment Of The Value Of a Day 14 Bone Marrow In Newly Diagnosed AML. <i>Blood</i> , 2013, 122, 5002-5002.	1.4	1
122	Adhesion Of Acute Myeloid Leukemia Blasts To E-Selectin In The Vascular Niche Enhances Their Survival By Mechanisms Such As Wnt Activation. <i>Blood</i> , 2013, 122, 61-61.	1.4	29
123	Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7021-7021.	1.6	6
124	Phase 2 Study Of Early Discharge and Outpatient Management Of Adult Patients Following Intensive Induction Chemotherapy For MDS and Non-APL AML. <i>Blood</i> , 2013, 122, 2932-2932.	1.4	0
125	Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center. <i>Blood</i> , 2013, 122, 64-64.	1.4	2
126	Mcl-1 Dependence Predicts Response To Vorinostat and Gemtuzumab Ozogamicin In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1305-1305.	1.4	1

#	ARTICLE	IF	CITATIONS
127	Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. Clinical Advances in Hematology and Oncology, 2013, 11, 571-7.	0.3	33
128	Gemtuzumab Ozogamicin: Time to Resurrect?. Journal of Clinical Oncology, 2012, 30, 3921-3923.	1.6	95
129	Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood, 2012, 119, 6198-6208.	1.4	273
130	Treatment of AML: resurrection for gemtuzumab ozogamicin?. Lancet, The, 2012, 379, 1468-1469.	13.7	20
131	Intensity of conditioning for allogeneic haemopoietic cell transplantation. Lancet Oncology, The, 2012, 13, 966-968.	10.7	5
132	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2012, 87, 89-99.	4.1	127
133	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2012, 120, 48-48.	1.4	64
134	Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 673-673.	1.4	90
135	Acute Myeloid Leukemia (AML). , 2012, , 1-36.		1
136	Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of "Acute Myeloid Leukemia, Not Otherwise Specified" in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center. Blood, 2012, 120, 540-540.	1.4	0
137	Cyclosporine Modulation of Multidrug Resistance in Combination with Pravastatin, Mitoxantrone, and Etoposide for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study. Blood, 2012, 120, 4343-4343.	1.4	0
138	What is the optimal induction strategy for older patients?. Best Practice and Research in Clinical Haematology, 2011, 24, 515-522.	1.7	1
139	The times they are a-changin'. Blood, 2011, 117, 1774-1775.	1.4	0
140	Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood, 2011, 118, 1490-1494.	1.4	100
141	Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 1190-1197.	1.6	351
142	Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment. Journal of Clinical Oncology, 2011, 29, 4417-4424.	1.6	287
143	High Cytogenetic or Molecular Genetic Risk Acute Myeloid Leukemia. Hematology American Society of Hematology Education Program, 2010, 2010, 474-480.	2.5	15
144	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood, 2010, 116, 2420-2428.	1.4	70

#	ARTICLE	IF	CITATIONS
145	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010, 115, 453-474.	1.4	2,963
146	Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 1766-1771.	1.6	187
147	Effective Treatment of Acute Promyelocytic Leukemia With All- <i>Trans</i> -Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. <i>Journal of Clinical Oncology</i> , 2009, 27, 504-510.	1.6	355
148	Using short-term response information to facilitate adaptive randomization for survival clinical trials. <i>Statistics in Medicine</i> , 2009, 28, 1680-1689.	1.6	54
149	AML in older patients: Are we making progress?. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 529-536.	1.7	29
150	Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. <i>Blood</i> , 2009, 113, 28-36.	1.4	192
151	Accounting for patient heterogeneity in phase II clinical trials. <i>Statistics in Medicine</i> , 2008, 27, 2802-2815.	1.6	38
152	New Drugs in Acute Myeloid Leukemia. <i>Seminars in Oncology</i> , 2008, 35, 439-448.	2.2	17
153	Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1263-1265.	3.5	40
154	Relapse and death during first remission in acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 633-634.	3.5	26
155	Impact of Pre-Transplant Minimal Residual Disease Assessed by Flow Cytometry on Outcome Following Myeloablative Hematopoietic Cell Transplantation for Patients with AML-CR1.. <i>Blood</i> , 2008, 112, 3253-3253.	1.4	4
156	Response in acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 113-7.	0.3	4
157	Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). <i>Blood</i> , 2007, 109, 1395-1400.	1.4	249
158	Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. <i>Blood</i> , 2006, 107, 3469-3473.	1.4	371
159	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome.. <i>Cancer</i> , 2006, 106, 1090-1098.	4.1	550
160	Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. <i>Cancer</i> , 2005, 104, 1442-1452.	4.1	429
161	Use of arsenic trioxide (As ₂ O ₃) in the treatment of patients with acute promyelocytic leukemia. <i>Cancer</i> , 2003, 97, 2218-2224.	4.1	169
162	Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4642-4649.	1.6	2,425

#	ARTICLE	IF	CITATIONS
163	Adaptive Randomized Study of Idarubicin and Cytarabine Versus Troxacitabine and Cytarabine Versus Troxacitabine and Idarubicin in Untreated Patients 50 Years or Older With Adverse Karyotype Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 1722-1727.	1.6	86
164	New designs for phase 2 clinical trials. <i>Blood</i> , 2003, 102, 442-448.	1.4	107
165	Experience with gemtuzumab ozogamycin (â€œmylotargâ€) and all-trans retinoic acid in untreated acute promyelocytic leukemia. <i>Blood</i> , 2002, 99, 4222-4224.	1.4	173
166	Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. <i>Blood</i> , 2002, 99, 4343-4349.	1.4	141
167	Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. <i>Blood</i> , 2000, 95, 72-77.	1.4	97
168	Implications of Potential Cure in Acute Myelogenous Leukemia: Development of Subsequent Cancer and Return to Work. <i>Blood</i> , 1997, 90, 4719-4724.	1.4	78